Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael B. Atkins, M.D.
Beth Israel Deaconess Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hadassah Medical Center
Jerusalem, Israel
- Chaim Sheba Medical Center
Tel Litwinsky, Israel
- Yale University School of Medicine, Section of Med Onc.
New Haven, Connecticut, United States
- Moffitt Cancer Center Cutaneous Oncology Department
Tampa, Florida, United States
- Northwestern Memorial Hospital
Chicago, Illinois, United States
- the University of Chicago
Chicago, Illinois, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Mass General Hospital
Boston, Massachusetts, United States
- Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Ruttenberg Cancer Clinic - the Mount Sinai Hospital
New York, New York, United States
- Providence Cancer Center
Portland, Oregon, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
- Baylor Univesity Medical Center
Dallas, Texas, United States
- University of Virginia Health System / Human Immune Therapy Center
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 31 Aug 2013
- Completion
- 31 Aug 2013
- Last update posted
- 21 Jan 2016
- Registered enrollment
- 103
- Registry id
- NCT01435369
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.